Genscript Biotech Balance Sheet Health
Financial Health criteria checks 4/6
Genscript Biotech has a total shareholder equity of $2.0B and total debt of $769.7M, which brings its debt-to-equity ratio to 37.7%. Its total assets and total liabilities are $3.4B and $1.3B respectively.
Key information
37.7%
Debt to equity ratio
US$769.73m
Debt
Interest coverage ratio | n/a |
Cash | US$1.93b |
Equity | US$2.04b |
Total liabilities | US$1.34b |
Total assets | US$3.39b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: G51's short term assets ($2.4B) exceed its short term liabilities ($494.8M).
Long Term Liabilities: G51's short term assets ($2.4B) exceed its long term liabilities ($848.1M).
Debt to Equity History and Analysis
Debt Level: G51 has more cash than its total debt.
Reducing Debt: G51's debt to equity ratio has increased from 2.1% to 37.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: G51 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if G51 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.